about
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1Heimlich valve and pneumothoraxTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapyExpression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).Use of proteins as biomarkers and their role in carcinogenesis.Enhancement of Intratumoral Chemotherapy with Cisplatin with or without Microwave Ablation and Lipiodol. Future Concept for Local Treatment in Lung Cancer.Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?Pacemaker insertion.Minimally invasive procedures.Pneumothorax: an up to date "introduction".Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stageDefining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients.Leiomyosarcoma as a second metachronous malignant neoplasm following colon adenocarcinoma. A case report and review of the literature.Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Acquired ichthyosis triggered by an osseous hemangiopericytoma: a case report and review of the literature.Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.Revisiting bleomycin from pathophysiology to safe clinical use.Chest drainage systems in use.Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).Novel therapeutic approaches in chondrosarcoma.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.Pseudomonas fluorescens infections in clinical practice.Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.Wide dissemination of linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent ST22 clone.Pneumothorax from diagnosis to treatment, hands on course: Part II.Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).Advances in the treatment of soft tissue sarcoma: focus on eribulin.Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.Dissemination of linezolid-dependent, linezolid-resistant Staphylococcus epidermidis clinical isolates belonging to CC5 in German hospitals.
P50
Q24804828-7407992A-76E0-414B-A5BD-E151F4F52BC1Q26858993-EEAC3048-9D68-4DC8-BA46-43CACDC9005DQ27851526-8AC43124-121D-41C9-8D67-9776934BDC5DQ34367452-204B4131-124B-4EAA-B849-BEABD3444A13Q34784895-DFDC9BAF-9C70-4368-991C-B500E914B10EQ35051258-B49C63F2-2432-45CF-99FD-FCB1E08716DEQ35148094-4C0322C0-6A97-4D64-A3F7-4E23355858D7Q35169177-9DBDCD27-154B-4ED6-BD5B-1B070EFF0489Q35238087-2880B065-09AE-4A63-A168-F185CDA87F23Q35238098-77423CFD-539F-4F47-B889-B02A243F18ABQ35625752-80695694-FD2A-484D-9782-7FCBDDE4C176Q35631635-CC24D296-428F-49C4-B73A-578638AA540DQ36085452-17155F1E-D3A9-4E7C-9852-2A0ACA5C2E78Q36674053-0B6C297C-06AB-4208-8CBB-118F17F1D117Q36924926-493E6B3B-D09B-4790-A030-9E5955A495FBQ36947812-498C2547-0951-41BF-836C-F66343CFC56FQ37603344-11A51DAF-2247-4669-8350-D5E323D9A41AQ37701702-9E2EE5E5-53E3-4090-82A8-07D45676CD97Q37715274-3C8439AD-9A47-4065-8A78-070359BE006DQ38047411-A081B64E-582E-4789-829B-08328AD75B5CQ38073439-21133528-6201-42F0-9EB1-14ABCB8A9EEEQ38393295-D3B80751-6126-4435-B68B-346172886D48Q38449775-CBD74B10-6534-468B-9E30-E5C87A4D22E5Q38688750-7B1013FD-1F5F-473D-9B0F-B2D4E64DE9A5Q38764510-044AD6C9-2643-475A-8080-970E8141317AQ39257661-0CA795D3-8C82-45E6-A488-2E3E5BC6E587Q39364336-BFF5AC1E-905B-4579-ABDE-4D3F1E2E0C42Q39638185-4E5A128C-CB84-4F3A-873E-0E0C29C573D6Q40081917-2CDDC3BD-691A-43AE-9C36-56A2CABF8A58Q40491675-B1DB82B9-5C77-417B-B547-CF32D7AEAFA6Q40700785-8F2932FC-D35D-4139-8F4F-45AB199C51ECQ41466000-29129A8A-18BE-4DA4-A7C4-9027E264130DQ42246091-A3131B50-EE66-4311-9FAE-6CF99BBF6312Q44746894-ECCE0CDF-FE5F-465C-AFA3-EB660D618E83Q45927534-4EBAF491-BCF6-43CE-82B9-297962595690Q48128054-12E3B74C-E4E8-4181-AB2C-1CF581DD8AA9Q49261685-508F6601-CBC1-4B6F-A35E-360D9C097773Q51652607-83CADA67-044C-4B43-8A6D-88BA135C7861Q51714855-F0A1A2F7-4930-412C-A9B8-BE30125C237FQ52390229-71249B93-D159-4597-9091-2AA25AFAC2A6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vasilis Karavasilis
@ast
Vasilis Karavasilis
@en
Vasilis Karavasilis
@es
Vasilis Karavasilis
@nl
type
label
Vasilis Karavasilis
@ast
Vasilis Karavasilis
@en
Vasilis Karavasilis
@es
Vasilis Karavasilis
@nl
prefLabel
Vasilis Karavasilis
@ast
Vasilis Karavasilis
@en
Vasilis Karavasilis
@es
Vasilis Karavasilis
@nl
P106
P1153
57192407246
57197839147
P31
P496
0000-0002-5806-9399